I learned that 136 million people—about one in three Americans—have diabetes or prediabetes. Many are unaware.

The consensus estimate for DexCom’s current full-year earnings is $1.69 per share. Leerink Partnrs also issued estimates for DexCom’s FY2027 earnings at $2.77 EPS and FY2028 earnings at $3.14 EPS.

Revenue growth and solid market position highlight DexCom's operational strengths. Investments in R&D and international expansion reflect strategic opportunities. Patent litigation and market ...

Revenue growth and solid market position highlight DexCom's operational strengths. Investments in R&D and international expansion reflect strategic opportunities. Patent litigation and market ...

On Friday, TD Cowen maintained a positive outlook on DexCom (NASDAQ:DXCM) shares, with a reiterated Buy rating and a $100.00 price target. DexCom's third-quarter results slightly surpassed Wall Street ...

DexCom, Inc. DXCM reported better-than-expected third-quarter results on Thursday. DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents.

On Friday, TD Cowen maintained a positive outlook on DexCom (NASDAQ:DXCM) shares, with a reiterated Buy rating and a $100.00 price target. DexCom's third-quarter results slightly surpassed Wall ...

DexCom's stock has declined 35% since my last bearish article, validating my "Sell" rating, though past bearish calls were incorrect as the stock previously doubled and tripled. Q3 results showed ...

On Friday, Bernstein SocGen Group adjusted its stock price target for DexCom (NASDAQ: DXCM), a medical device company specializing in glucose monitoring systems. The new price target is set at $86 ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...